Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Bando et al. (ALTAIR trial)
PMID 42260101 | Phase 3 RCT | Nature Medicine 🔴 EARLY_CANCER_DETECTION
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First Phase 3 RCT to directly test ctDNA-guided post-adjuvant escalation in CRC; negative result is itself highly informative and constrains the field |
| Clinical Relevance | 8 | Directly addresses an emerging clinical paradigm (treat ctDNA+ MRD-positive CRC patients); the null result changes how clinicians should interpret ctDNA positivity in this window |
| Population Reach | 8 | CRC is the 3rd most common cancer globally; ctDNA monitoring is rapidly entering clinical practice; affects a large and growing patient subpopulation |
| Implementation Speed | 7 | ctDNA assays (Signatera) are already in clinical use; this result has immediate impact on whether to treat ctDNA+ patients with FTD/TPI in the post-adjuvant window |
| Evidence Strength | 8 | Phase 3 RCT, double-blind, embedded in CIRCULATE-Japan platform; well-powered with pre-specified endpoints; limitation: primary endpoint narrowly missed significance (p=0.107), abstract-only access |
Key quantitative result: HR=0.79 (95% CI 0.60–1.05, p=0.107); median DFS 9.30 vs 5.55 months. Numerically meaningful but statistically non-significant.
External validation: Single trial; CIRCULATE-Japan platform provides robust infrastructure. No replication yet.
Main limitation: Primary endpoint not met; abstract-only — full statistical analysis, subgroup data, and secondary endpoints unavailable. The numeric trend (HR 0.79, ~3.75-month DFS difference) leaves genuine clinical ambiguity.
Equity implications: Signatera ctDNA assay is commercially available primarily in high-income settings; patients in low/middle-income countries have negligible access to ctDNA-guided strategies. The trial population is Japanese — biological and treatment context generalizability to Western/diverse populations needs evaluation.
Evidence Maturity: ✅ Confirmed Validated (Phase 3 RCT, peer-reviewed, high-impact journal)
OpenClaw triage_score: 8 | Phase 2 composite: 7.9
Article 2 — Guo et al. (Toripalimab + Cetuximab HNSCC)
PMID 42260304 | Phase 1b/2 | Signal Transduction and Targeted Therapy 🟠 NOVEL_TREATMENT
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | PD-1 + EGFR combinations are a known strategy in HNSCC; toripalimab is PD-1 class; novelty is the specific agent combination and first-line PD-L1+ cohort data |
| Clinical Relevance | 7 | R/M HNSCC is a high-unmet-need setting; 60% ORR in platinum-refractory disease and 14.1-month OS are clinically meaningful benchmarks; relevant for second-line treatment decisions |
| Population Reach | 6 | HNSCC is globally common (~900K cases/year); platinum-refractory R/M is a smaller but important subpopulation with limited options |
| Implementation Speed | 4 | Requires Phase 3 confirmation; toripalimab is not approved in all markets; China-centric enrollment limits immediate Western adoption |
| Evidence Strength | 6 | Phase 1b/2, open-label, multicenter, n=88; ORR data are promising but without randomized comparator; PD-L1 biomarker selection adds rigor |
Key quantitative result: ORR 60.0% (platinum-refractory); ORR 44.2% (first-line PD-L1+); median OS 14.1 and 18.1 months respectively.
External validation: No independent replication; Chinese multicenter only.
Main limitation: No randomized comparator arm; open-label design; generalizability to Western/diverse populations uncertain; phase 1b/2 sample size.
Equity implications: Toripalimab is primarily available in China/Asia-Pacific; Western patients cannot immediately access this combination. HPV-associated HNSCC subgroup outcomes not clearly stratified in abstract.
Evidence Maturity: Revised to Exploratory (Phase 1b/2, no comparator arm — not yet Validated)
OpenClaw triage_score: 7 | Phase 2 composite: 5.9
Article 3 — Wu et al. (FedOG Federated Liver Lesion Detection)
PMID 42260279 | Multi-institutional technical validation | NPJ Digital Medicine 🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Orthogonal gradient decomposition applied to federated learning for incomplete multi-phase CT is methodologically novel; addresses a real architectural gap in federated medical AI |
| Clinical Relevance | 5 | Liver lesion detection improvement is clinically important, but Dice score improvements of 1–3% are modest; no clinical outcome data or reader-study validation |
| Population Reach | 7 | Liver cancer is globally prevalent; federated approach particularly benefits lower-resource institutions that lack full multi-phase CT protocols |
| Implementation Speed | 4 | Federated infrastructure requires institutional IT investment; regulatory clearance for AI diagnostic tools adds time; no prospective validation yet |
| Evidence Strength | 6 | Large dataset (n=3,668 scans, 5 institutions); multi-institutional retrospective; technically rigorous; no prospective clinical validation or outcome-linked endpoints |
Key quantitative result: Dice improvement: +1.67% (real-world clinical dataset), +1.13–3.03% (public datasets) vs. standard federated learning baseline.
External validation: Tested on 2 public datasets plus internal; no independent external prospective validation.
Main limitation: Retrospective technical validation only; no prospective study; no direct patient outcome or radiologist performance comparison.
Equity implications: Potentially high equity value — federated learning allows under-resourced institutions with incomplete CT phases to participate in collaborative AI without sharing patient data. This directly addresses a global resource disparity in medical imaging AI.
Evidence Maturity: Confirmed Exploratory (technical validation; not yet clinically validated)
OpenClaw triage_score: 7 | Phase 2 composite: 5.8
Article 4 — Steemers et al. (Burkitt Lymphoma scWGS)
PMID 42259789 | scWGS + phylogenetic analysis | Nature Communications ⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | Single-cell resolution of convergent evolutionary dynamics in pediatric Burkitt lymphoma is genuinely novel; demonstrates independent mutational convergence at both SNV and CNV levels |
| Clinical Relevance | 4 | Foundational biology; no immediate clinical application; implications for resistance mechanisms are speculative at this stage |
| Population Reach | 5 | Burkitt lymphoma is relatively rare (particularly in high-income settings), though more common in equatorial Africa; pediatric cancer with high unmet need in LMIC |
| Implementation Speed | 2 | Basic science discovery; 5–10+ years from any clinical translation |
| Evidence Strength | 6 | Methodologically sophisticated (scWGS + bulk WGS integration, phylogenetic analysis); n=250 single cells; limited by small patient number and exploratory design |
Key quantitative result: Accelerated mutation accumulation post-MRCA; extensive early intratumoral heterogeneity via convergent evolution at both point mutation and CNV levels (no single quantitative effect size available in abstract).
External validation: Integrated with healthy B-cell reference (n=157 clonally expanded cells); single-center cohort.
Main limitation: Small patient cohort; observational/exploratory; no therapeutic intervention or clinical outcome endpoint.
Equity implications: Burkitt lymphoma disproportionately affects children in sub-Saharan Africa (EBV-associated endemic form); mechanistic insights from a Dutch pediatric center may have limited direct applicability to the highest-burden populations without inclusive sampling.
Evidence Maturity: Confirmed Exploratory
OpenClaw triage_score: 7 | Phase 2 composite: 5.2
Article 5 — Abuloha et al. (SMA DMT Budget Impact)
PMID 42260056 | Budget impact analysis | Clinical Drug Investigation 🟡 UNDERSERVED_POPULATION
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Budget impact analyses of SMA DMTs exist; this adds 5-year + lifetime horizon comparison across all three agents; incremental novelty |
| Clinical Relevance | 6 | Directly relevant to formulary/access decision-making for payers and health systems; risdiplam's counterintuitive high lifetime cost finding is actionable |
| Population Reach | 5 | SMA Type 1 is rare (~1:6,000–10,000 births); but within the SMA community, access to DMTs is a critical unmet need; high per-patient impact |
| Implementation Speed | 7 | Budget impact models are immediately usable by payers and policy makers; findings can influence formulary decisions now |
| Evidence Strength | 5 | State-transition model with 5-year and lifetime horizons; model quality depends on input data quality; not yet externally validated; abstract-only |
Key quantitative result: 5-year per-patient added cost vs. BSC: onasemnogene $2.18M, nusinersen $1.51M, risdiplam $1.17M. Lifetime: risdiplam $5.86M, onasemnogene $3.16M, nusinersen $3.05M.
External validation: Model-based; no external validation of assumptions.
Main limitation: Cross-sectional budget model; US payer perspective only; key assumptions about long-term efficacy and survival may not reflect real-world experience; international generalizability limited.
Equity implications: The enormous cost differentials raise stark access equity questions — particularly for risdiplam, which has the highest lifetime cost despite being the most accessible route of administration. LMIC patients may be disproportionately impacted by cost barriers.
Evidence Maturity: Downgraded to Exploratory (model-based analysis; not empirical outcome data)
OpenClaw triage_score: 6 | Phase 2 composite: 5.4
Article 6 — Gulyás et al. (Serum Biomarkers in Melanoma)
PMID 42259989 | Systematic Review & Meta-analysis | Scientific Reports ⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Confirms established knowledge; ctDNA prognostic value in melanoma is not new; multi-biomarker comparison across LDH, S100B, NLR, IL-6 and ctDNA adds modest comparative value |
| Clinical Relevance | 6 | Quantified HRs across biomarkers useful for clinical prioritization; ctDNA HR 2.61 is a strong and actionable summary estimate for clinical utility |
| Population Reach | 6 | Melanoma incidence is rising globally; all melanoma patients potentially benefit from better prognostic stratification |
| Implementation Speed | 6 | LDH and NLR are already in routine use; ctDNA monitoring is expanding; meta-analysis findings could inform clinical guidance updates |
| Evidence Strength | 7 | PRISMA + PROSPERO registered meta-analysis; multivariable analysis confirmed; strongest design in class for evidence synthesis |
Key quantitative result: ctDNA HR 2.61 (95% CI 1.90–3.58) for reduced OS; LDH, S100B, NLR, IL-6 all significantly associated with reduced OS/PFS.
External validation: Meta-analytic design inherently pools across multiple studies; PROSPERO registration adds rigor.
Main limitation: Heterogeneity across included studies (different ctDNA platforms, treatment eras, patient populations); abstract-only — cannot assess publication bias analysis.
Equity implications: LDH and NLR are globally accessible; ctDNA monitoring remains a high-income-country tool; findings reinforce equity gap in prognostic monitoring.
Evidence Maturity: Confirmed Validated
OpenClaw triage_score: 6 | Phase 2 composite: 5.8
Article 7 — Shi et al. (DL Spatiotemporal Breast Cancer Lung Mets)
PMID 42260099 | Retrospective DL multicenter validation | NPJ Precision Oncology 🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Registration-free longitudinal multi-lesion tracking is technically elegant; addresses known limitation of RECIST 1.1; spatiotemporal patient-level framing is incremental but meaningful |
| Clinical Relevance | 6 | Directly applicable to treatment response monitoring in metastatic breast cancer; patient-level assessment (not lesion-level) is clinically more meaningful |
| Population Reach | 6 | Metastatic breast cancer with lung mets is a substantial subpopulation globally; treatment monitoring is a universal clinical need |
| Implementation Speed | 4 | Multicenter validation is encouraging but no prospective outcome data; regulatory approval and clinical workflow integration required |
| Evidence Strength | 5 | Multicenter (4 centers) retrospective validation; no sample size stated; no prospective or outcome-linked validation; abstract-only |
Key quantitative result: Outperformed state-of-the-art methods on institutional + public datasets (specific Dice/AUC values not available in abstract).
External validation: 4-center validation is positive; all centers appear to be Chinese institutions — geographic generalizability uncertain.
Main limitation: All-retrospective; no sample size stated; no clinical outcome endpoints (survival, treatment decision change); Chinese-centric validation.
Equity implications: Automated registration-free monitoring could reduce radiologist workload and improve consistency in lower-resource settings, but software deployment barriers remain.
Evidence Maturity: Confirmed Exploratory
OpenClaw triage_score: 6 | Phase 2 composite: 5.4
Article 8 — Ankoji et al. (LAM-CATNet Mammography)
PMID 42259999 | DL benchmark study | Scientific Reports ⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Transformer-CNN hybrid architectures for mammography are well-explored; lambda distribution integration is a minor methodological variant |
| Clinical Relevance | 4 | Benchmark-only; no clinical dataset, no reader comparison, no outcome validation; high AUC on public benchmarks does not translate directly to clinical utility |
| Population Reach | 7 | Breast cancer screening is a universal population health priority affecting hundreds of millions of women globally |
| Implementation Speed | 3 | Requires prospective clinical validation, regulatory approval; benchmark-only studies are far from deployment |
| Evidence Strength | 4 | Public benchmark datasets only (CBIS-DDSM, MIAS); no external clinical validation; classification_confidence medium; well-known overfitting risk on public benchmarks |
Key quantitative result: Dice 0.786 (CBIS-DDSM), 0.869 (MIAS); classification accuracy 94.7%, AUC 0.982.
External validation: Public benchmarks are widely used but not clinical validation; no independent test set.
Main limitation: Benchmark-only validation; public datasets do not represent real-world clinical diversity; risk of overfitting; no clinical outcome or reader comparison.
Equity implications: Mammography AI could improve access to expert-level screening interpretation in low-resource settings — if clinically validated and deployed equitably, which this study does not yet address.
Evidence Maturity: Confirmed Exploratory
OpenClaw triage_score: 6 | Phase 2 composite: 4.6
Article 9 — Monteverdi et al. (Brain Network Modeling in MCI)
PMID 42260290 | Cross-sectional cohort | Scientific Reports ⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Combining graph theory + virtual brain modeling (TVB) for subject-specific MCI phenotyping is methodologically novel; R²~70% correlation with clinical and biomarker measures is noteworthy |
| Clinical Relevance | 5 | Subject-specific stratification of MCI could improve trial enrollment and personalized intervention; not ready for clinical use |
| Population Reach | 8 | Dementia/MCI represents one of the largest global healthcare challenges; ~55M people living with dementia worldwide |
| Implementation Speed | 3 | Computational complexity of virtual brain modeling; single-center only; requires significant validation before clinical adoption |
| Evidence Strength | 4 | Single-center; sample size unstated; cross-sectional design; no longitudinal outcome validation |
Key quantitative result: R²~70% for MMSE score correlation; parameters correlated with Aβ and τ biomarkers.
External validation: None reported; single-center (IRCCS Mondino Foundation, Pavia).
Main limitation: Single center; small/unstated sample size; cross-sectional — cannot assess predictive value for conversion to AD; computational pipeline not standardized.
Equity implications: MCI/dementia disproportionately affects lower-income countries (70% of dementia burden in LMIC); this methodology requires expensive MRI and computational infrastructure, limiting near-term equity benefit.
Evidence Maturity: Confirmed Exploratory
OpenClaw triage_score: 6 | Phase 2 composite: 5.2
Article 10 — Kurmuş et al. (SII in Mycosis Fungoides)
PMID 42259538 | Retrospective cohort | Annals of Clinical and Laboratory Science 🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | SII as prognostic marker is well-established in other malignancies; application to mycosis fungoides is new but conceptually incremental |
| Clinical Relevance | 6 | High AUC (0.891) for staging discrimination; CBC-derived and immediately calculable; directly actionable in MF clinical practice with minimal cost |
| Population Reach | 3 | Mycosis fungoides is a rare CTCL; but within this population, easy staging tools have real value |
| Implementation Speed | 7 | SII is calculated from routine CBC differential; zero additional cost or technology needed; implementable immediately if validated |
| Evidence Strength | 4 | Single-center retrospective; n=126; no external validation; tertiary center referral bias likely |
Key quantitative result: SII AUC 0.891 (p<0.001), sensitivity 80.95%, specificity 88.57% at cut-off 891.02; outperformed NLR (AUC not stated) and LMR.
External validation: None; single Turkish tertiary center.
Main limitation: Single-center retrospective; referral bias; no external validation; MF staging can be complex and SII is unlikely to replace histopathology/immunophenotyping.
Equity implications: SII's CBC derivability is a major equity strength — applicable in any healthcare setting globally with no additional cost.
Evidence Maturity: Confirmed Exploratory
OpenClaw triage_score: 5 | Phase 2 composite: 4.8
Article 11 — Daoud & Pamuk (CAR-T in SLE Review)
PMID 42260211 | Narrative review | Clinical Rheumatology 🟠 NOVEL_TREATMENT
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | CAR-T in autoimmune disease is a genuinely emerging paradigm; this review synthesizes early clinical evidence for a novel application of cellular therapy |
| Clinical Relevance | 6 | Refractory SLE has very limited treatment options; if even a fraction of early CAR-T signals translate, this is practice-changing for a small but severely affected population |
| Population Reach | 5 | SLE affects ~5M people globally; the refractory subpopulation is smaller but has significant morbidity |
| Implementation Speed | 3 | Manufacturing complexity, cost, regulatory hurdles; well-designed trials cited as prerequisite; review does not add new data |
| Evidence Strength | 3 | Narrative review only; no new primary data; evidence base is primarily case series and early phase trials (Mackensen 2022, Müller 2024) |
Key quantitative result: N/A (review); cited primary studies suggest sustained drug-free remission in early case series.
External validation: N/A.
Main limitation: Narrative review; no systematic search; no meta-analytic synthesis; evidence base is still early-stage.
Equity implications: CAR-T manufacturing costs ($300K–$500K+ per patient) create severe access inequities; refractory SLE disproportionately affects women of color.
Evidence Maturity: Confirmed Exploratory
OpenClaw triage_score: 5 | Phase 2 composite: 4.6
Article 12 — Deng et al. (Metabolic Indices & Circadian Syndrome)
PMID 42260226 | Cross-sectional | Hormones (Athens) ⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | CTI as mediator between metabolic indices and circadian syndrome is a novel framing, but circadian syndrome and metabolic risk associations are well-explored |
| Clinical Relevance | 3 | Cross-sectional design; cannot establish causality; circadian syndrome is not yet a widely operationalized clinical construct |
| Population Reach | 6 | Metabolic syndrome and sleep/circadian disruption are global public health challenges; n=6,507 from CHARLS provides reasonable representativeness of Chinese elderly |
| Implementation Speed | 3 | Hypothesis-generating only; requires prospective validation before clinical application |
| Evidence Strength | 5 | Large n=6,507; established CHARLS dataset; mediation analysis adds mechanistic framing; but cross-sectional design precludes causal inference |
Key quantitative result: CTI indirect effects: 20.8–86.5% of total association with circadian syndrome across metabolic indices.
External validation: No; single wave (CHARLS 2015).
Main limitation: Cross-sectional — no causal inference; Chinese-specific population; circadian syndrome definition varies across studies.
Equity implications: Findings reflect Chinese middle-aged/elderly population; limited direct applicability to other ethnic groups.
Evidence Maturity: Confirmed Exploratory
OpenClaw triage_score: 5 | Phase 2 composite: 4.2
Article 13 — Witt et al. (Down Syndrome Co-occurring Conditions)
PMID 42260322 | Cross-sectional survey | American Journal of Medical Genetics Part A 🟡 UNDERSERVED_POPULATION
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Co-occurring condition prevalence in DS is well documented; the novel finding is the lack of correlation between guideline adherence and health scores |
| Clinical Relevance | 5 | The guideline adherence ≠ health outcomes finding is potentially important for redesigning DS care standards; but caregiver-reported design limits conclusions |
| Population Reach | 5 | Down syndrome affects ~1:700 births; ~6M people globally; national US sample adds representativeness |
| Implementation Speed | 5 | Survey findings could inform guideline revision and care model redesign relatively quickly |
| Evidence Strength | 4 | n=542; cross-sectional; caregiver-reported; secondary analysis; moderate risk of recall and response bias |
Key quantitative result: Guideline adherence not correlated with health scores (p=0.13); father caregiver and better parent health correlated with better child health outcomes.
External validation: None; national survey but single-wave.
Main limitation: Caregiver-reported outcomes; cross-sectional; guideline adherence self-reported; limited by response bias.
Equity implications: Directly addresses social determinants of health in DS — a population with significant care disparities, particularly across race/ethnicity and socioeconomic status. The social factors analysis is a genuine equity contribution.
Evidence Maturity: Confirmed Exploratory
OpenClaw triage_score: 5 | Phase 2 composite: 4.6
Article 14 — Mohyuddin et al. (Cilta-cel in Myeloma Commentary)
PMID 42260185 | Commentary/Perspective | Nature Reviews Clinical Oncology ⬜ NONE (title-only)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | — | Cannot assess; title-only |
| Clinical Relevance | — | Cannot assess; title-only; Nat Rev Clin Oncol prestige suggests clinical relevance |
| Population Reach | — | Multiple myeloma = substantial population; cannot score |
| Implementation Speed | — | Cannot assess |
| Evidence Strength | 2 | Title-only; commentary format; no primary data |
Note: All scores suppressed per title-only rule. classification_confidence = low. Flagged for revisit when abstract is indexed.
Evidence Maturity: Cannot confirm — Exploratory retained by default
OpenClaw triage_score: 3 | Phase 2 composite: Not rankable
Article 15 — Zeng & Feng (PROTAC DPP-4 Degradation)
PMID 42260272 | Drug development/in vitro | Journal of Medicinal Chemistry ⚪ PROMISING_PRELIMINARY
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | PROTAC application to DPP-4 (rather than inhibition) is mechanistically novel; targeted protein degradation in metabolic disease is an emerging concept |
| Clinical Relevance | 2 | In vitro only; no animal or clinical data; GLP-1 pathway adjacency is relevant but indirect |
| Population Reach | 8 | Type 2 diabetes affects ~500M people globally; DPP-4 is a validated target |
| Implementation Speed | 1 | Lab-stage chemistry; 10+ years to any clinical translation if pursued |
| Evidence Strength | 3 | In vitro/medicinal chemistry only; no in vivo data; cannot exceed 5 on Clinical Relevance per non-human cap |
Key quantitative result: Not available (conceptual/early development approach per abstract).
External validation: None.
Main limitation: Entirely preclinical; no animal efficacy data; PROTAC oral bioavailability and in vivo stability are known challenges for this modality.
Equity implications: If successfully developed, DPP-4-targeting PROTACs would enter an already crowded T2DM space; access equity would depend on cost and manufacturing.
Evidence Maturity: Confirmed Exploratory
OpenClaw triage_score: 4 | Phase 2 composite: 3.8
PHASE 3 — Ranking
Conflict Summary
Two articles in this batch address partially overlapping ctDNA territory (Articles 1 and 6). They are not in conflict — Article 1 (ALTAIR) tests whether ctDNA-positive status should trigger treatment escalation (answer: uncertain with FTD/TPI), while Article 6 (Gulyás meta-analysis) confirms ctDNA as a prognostic marker in a different cancer (melanoma). These findings are complementary: ctDNA is prognostically valid, but identifying positivity does not automatically mean a given treatment will work.
Ranked Impact Table
Composite Score Formula: Clinical Relevance ×0.30 + Population Reach ×0.25 + Scientific Novelty ×0.20 + Implementation Speed ×0.15 + Evidence Strength ×0.10
| Rank | Article | Flag | Impact Score | Clin. Rel. | Pop. Reach | Sci. Novel. | Impl. Speed | Evid. Strength | OpenClaw Score | Study Design |
|---|---|---|---|---|---|---|---|---|---|---|
| #1 | Bando et al. — ALTAIR ctDNA RCT (PMID 42260101) | 🔴 | 7.85 | 8 | 8 | 8 | 7 | 8 | 8 | Phase 3 RCT |
| #2 | Guo et al. — Toripalimab+Cetuximab HNSCC (PMID 42260304) | 🟠 | 6.05 | 7 | 6 | 6 | 4 | 6 | 7 | Phase 1b/2 trial |
| #3 | Gulyás et al. — Serum Biomarkers Melanoma (PMID 42259989) | ⬜ | 5.90 | 6 | 6 | 4 | 6 | 7 | 6 | Systematic review/meta-analysis |
| #4 | Wu et al. — FedOG Liver Lesion CT (PMID 42260279) | 🟢 | 5.75 | 5 | 7 | 7 | 4 | 6 | 7 | Multi-institutional technical validation |
| #5 | Abuloha et al. — SMA DMT Budget Impact (PMID 42260056) | 🟡 | 5.55 | 6 | 5 | 4 | 7 | 5 | 6 | Budget impact model |
| #6 | Shi et al. — DL Breast Cancer Lung Mets (PMID 42260099) | 🟢 | 5.40 | 6 | 6 | 6 | 4 | 5 | 6 | Retrospective DL multicenter validation |
| #7 | Steemers et al. — Burkitt Lymphoma scWGS (PMID 42259789) | ⚪ | 5.05 | 4 | 5 | 9 | 2 | 6 | 7 | scWGS + phylogenetic analysis |
| #8 | Monteverdi et al. — Brain Network MCI (PMID 42260290) | ⚪ | 5.00 | 5 | 8 | 6 | 3 | 4 | 6 | Cross-sectional cohort |
| #9 | Witt et al. — Down Syndrome Health (PMID 42260322) | 🟡 | 4.70 | 5 | 5 | 4 | 5 | 4 | 5 | Cross-sectional survey |
| #10 | Kurmuş et al. — SII in Mycosis Fungoides (PMID 42259538) | 🟢 | 4.70 | 6 | 3 | 4 | 7 | 4 | 5 | Retrospective cohort |
| #11 | Daoud & Pamuk — CAR-T in SLE Review (PMID 42260211) | 🟠 | 4.60 | 6 | 5 | 6 | 3 | 3 | 5 | Narrative review |
| #12 | Ankoji et al. — LAM-CATNet Mammography (PMID 42259999) | ⚪ | 4.55 | 4 | 7 | 5 | 3 | 4 | 6 | DL benchmark study |
| #13 | Deng et al. — Metabolic Indices & Circadian Syndrome (PMID 42260226) | ⬜ | 4.20 | 3 | 6 | 4 | 3 | 5 | 5 | Cross-sectional |
| #14 | Zeng & Feng — PROTAC DPP-4 (PMID 42260272) | ⚪ | 3.75 | 2 | 8 | 6 | 1 | 3 | 4 | In vitro drug development |
| NR | Mohyuddin et al. — Cilta-cel Commentary (PMID 42260185) | ⬜ | Not ranked | — | — | — | — | 2 | 3 | Commentary (title-only) |
Rank Justification Summaries
#1 — ALTAIR (Bando et al.): The only Phase 3 RCT in this batch, published in Nature Medicine, directly tests an already-emerging clinical practice — treating ctDNA-positive CRC patients with molecular residual disease. The negative result is not a failure; it is high-value evidence that constrains an incomplete clinical paradigm before it becomes embedded in practice. The HR of 0.79 with a 3.75-month numeric DFS advantage leaves open the question of whether FTD/TPI has a real but undersized effect, whether patient selection needs refinement, or whether a different agent is needed. This shapes future trial design across the entire ctDNA-guided treatment landscape. Scores of 8 across Clinical Relevance, Population Reach, Scientific Novelty, and Evidence Strength are justified.
Why it matters: Every year, thousands of CRC patients will have ctDNA testing after surgery. This trial tells clinicians — and trial designers — that reflexively treating all ctDNA-positive patients with FTD/TPI is not yet evidence-based, and that the field must do better before this paradigm becomes standard care.
#2 — Toripalimab+Cetuximab (Guo et al.): A Phase 1b/2 trial showing 60% ORR in platinum-refractory HNSCC is a noteworthy clinical signal in a setting where standard options are limited. The dual immune-EGFR targeting rationale is biologically sound. However, the open-label design, lack of comparator arm, and China-centric enrollment temper enthusiasm. This warrants Phase 3 monitoring.
Why it matters: Head and neck cancer is often diagnosed late and platinum resistance leaves patients with few options; a 60% response rate — if replicated — would represent a meaningful advance for this difficult-to-treat population.
#3 — Serum Biomarkers Melanoma (Gulyás et al.): A well-executed PROSPERO-registered meta-analysis providing the clearest quantitative summary to date of ctDNA's prognostic power in melanoma (HR 2.61). Evidence strength exceeds many other articles in this batch. Positions ctDNA monitoring as the strongest single prognostic tool while preserving the practical role of LDH in resource-limited settings.
Why it matters: Oncologists managing melanoma now have robust pooled evidence to justify ctDNA monitoring and to counsel patients on what elevated ctDNA means for their prognosis.
#4 — FedOG (Wu et al.): The largest federated liver lesion CT study to date, with meaningful equity implications for institutions lacking full multi-phase CT capabilities. Dice improvements are modest but the architectural innovation — orthogonal gradient decomposition — is technically significant. Near-term implementable for institutions already investing in federated AI infrastructure.
Why it matters: Most hospitals worldwide don't have complete CT protocols; this framework could bring AI-grade liver lesion detection to institutions previously locked out of collaborative AI training.
#5 — SMA Budget Impact (Abuloha et al.): The counterintuitive finding that risdiplam carries the highest lifetime budget impact despite lower annual costs is immediately actionable for formulary decision-makers. Provides the most comprehensive comparative DMT cost analysis to date in infantile SMA from a US payer perspective.
Why it matters: When a payer chooses between SMA therapies, the annual list price is not the whole story — this model shows lifetime cost can differ dramatically based on treatment duration.
(Ranks #6–14 follow a gradient of decreasing clinical maturity, population relevance, or evidence quality, as detailed in the scoring tables above.)